Search
umeclidinium/vilanterol (Anoro Ellipta)
FDA-approved recommended Dec 2013. [2]
Indications:
- treatment of chronic obstructive pulmonary disease
Dosage:
- 2 puffs once daily
Adverse effects:
- use with caution in patients with cardovascular disease
- safe for patients with cardiovascular disease
- myocardial infarction < 1%, more common in 1st 3 weeks
- not a risk in postmarketing experience
- paradoxical bronchospasm
- acute narrow-angle glaucoma
- worsening of urinary retention
Mechanism of action:
- combines long-acting antimuscarinic agent (umeclidinium) with a long-acting beta-agonist (vilanterol)
Notes:
- cost 280/month (2014)
General
LABA/LAMA combination
Database Correlations
PUBCHEM cid=71300746
References
- Physician's First Watch, September 12, 2013
David G. Fairchild, MD, MPH, Editor-in-Chief
Massachusetts Medical Society
http://www.jwatch.org
- FDA News Release: Dec. 18, 2013
FDA approves Anoro Ellipta to treat chronic obstructive
pulmonary disease
http://www.fda.gov/NewsEvents/Newsroom/PressAnnouncements/ucm379057.htm
- Prescriber's Letter 21(4): 2014
Inhalers for COPD
Detail-Document#: 300403
(subscription needed) http://www.prescribersletter.com
- Highlights of Prscribing Information
Anora Ellipta (umeclidiniumb & vilanterol powder) for oral inalation
https://gskpro.com/content/dam/global/hcpportal/en_US/Prescribing_Information/Anoro_Ellipta/pdf/ANORO-ELLIPTA-PI-PIL-IFU.PDF
Components
umeclidinium (Incruse Ellipta)
vilanterol